What is Sativex?
Sativex is an oromucosal spray derived from two strains of Cannabis sativa L., folium cum flore (cannabis leaf and flower) cultivated for their controlled proportions of the active compounds delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) (1).
Sativex is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Treatment with Sativex must be initiated and supervised by a physician with specialist expertise in treating this patient population (1).
NB. Sativex is a Schedule 4 Part 1 controlled drug. There are no additional requirements for prescription in the NHS other than those that apply to all Prescription Only Medicine (POMs). FP10PCD requirements do not apply when Sativex is prescribed privately. Acquisition or disposal of Sativex must be recorded for a minimum of 2 years. Pharmacists do not need to record Sativex in their controlled drug registers, although this is strongly recommended by the Home Office (2).
- Sativex Summary of Product Characteristics.
(last accessed February 2015)